HIF1A and cancer: Importantly, the different degree of HIF-1α activation in both hypoxic recipient cell lines after pretreatment with DOX-TEV but not with normoxic TEV (Figure 8A,D) support the role of chemotherapy-induced TEV in driving both homotypic and heterotypic cellular responses associated with resistance to cancer therapy and cancer aggressiveness [62,67,68,69].